A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Recruiting now Phase 3 NCT06528314
Run by Akero Therapeutics, Inc · for 18 to 80 · All sexes
What this study is about
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
Who can join (things the study team will check)
✅ You may be able to join if…
- Cohort 1: Biopsy proven compensated cirrhosis (fibrosis stage 4) due to NASH/MASH and NAS score of >=3 (at least 1 in each category) or evidence of steatosis and 2 current features of metabolic comorbidities
- Cohort 2: Biopsy proven or non-invasively diagnosed compensated cirrhosis (fibrosis stage 4) due to NASH/MASH
🚫 You may not be able to join if…
- Other causes of liver disease based on medical history and/or liver histology and/or central laboratory results
- Type 1 diabetes or unstable Type 2 diabetes
- Any current or prior history of decompensated liver disease Other inclusion and exclusion criteria may apply.
Where this trial is running
- Akero Clinical Study Site, Birmingham, Alabama, United States
- Akero Clinical Study Site, Dothan, Alabama, United States
- Akero Clinical Study Site, Chandler, Arizona, United States
- Akero Clinical Study Site, Flagstaff, Arizona, United States
- Akero Clinical Study Site, Peoria, Arizona, United States
- Akero Clinical Study Site, Scottsdale, Arizona, United States
- Akero Clinical Study Site, Tucson, Arizona, United States
- Akero Clinical Study Site, Tucson, Arizona, United States
- Akero Clinical Study Site, Tucson, Arizona, United States
- Akero Clinical Study Site, Tucson, Arizona, United States
- Akero Clinical Study Site, Conway, Arkansas, United States
- Akero Clinical Study Site, Jonesboro, Arkansas, United States
+ 310 more sites.
Who to contact
Akero Study Director · 650-487-6488 · AkeroSynchrony@akerotx.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06528314.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.